Search research articles
Contact Us
Filters
Showing results (161-170 of 174) with videos related to
Page
of 18
Sort By:
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Transplantation and Cellular Therapy
|
March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Binod Dhakal, Nina Shah, Ankit Kansagra, et al.
Nature Cancer
|
November 9, 2023
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M Boyle, David Coffey, et al.
Blood Cancer Discovery
|
June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestry
Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
JAMA Oncology
|
July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, Mark Roschewski, Adriana Zingone, et al.
The New England Journal of Medicine
|
September 28, 2022
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Cancer Cell
|
May 22, 2022
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Robert Stuver, Gunjan L Shah, Neha S Korde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2022
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Urvi A Shah, Kylee H Maclachlan, Andriy Derkach, et al.
JAMA Oncology
|
April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial
Ola Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Blood
|
April 21, 2025
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy
Kai Rejeski, Jaime Sanz, Teng Fei, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 174) with videos related to
Sort By:
Page
of 18
JAMA Oncology
|
September 16, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial
Dickran Kazandjian, Elizabeth Hill, Alexander Dew, et al.
Transplantation and Cellular Therapy
|
March 20, 2022
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Binod Dhakal, Nina Shah, Ankit Kansagra, et al.
Nature Cancer
|
November 9, 2023
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M Boyle, David Coffey, et al.
Blood Cancer Discovery
|
June 12, 2026
Genomic features do not account for differences in multiple myeloma risk by ancestry
Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, et al.
JAMA Oncology
|
July 17, 2015
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
Neha Korde, Mark Roschewski, Adriana Zingone, et al.
The New England Journal of Medicine
|
September 28, 2022
GPRC5D-Targeted CAR T Cells for Myeloma
Sham Mailankody, Sean M Devlin, Jonathan Landa, et al.
Cancer Cell
|
May 22, 2022
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Robert Stuver, Gunjan L Shah, Neha S Korde, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2022
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets
Urvi A Shah, Kylee H Maclachlan, Andriy Derkach, et al.
JAMA Oncology
|
April 15, 2021
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial
Ola Landgren, Malin Hultcrantz, Benjamin Diamond, et al.
Blood
|
April 21, 2025
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy
Kai Rejeski, Jaime Sanz, Teng Fei, et al.
Page
of 18